Applying this copy number cutoff to all tumor types represented in TCGA (Table 1) yielded MDM2 amplification rates far lower than those published previously [23], providing a more rationally defined threshold for enrolling patients into clinical trials designed to test whether MDM2 amplification affords enhanced sensitivity to MDM2 inhibition. Here, MDM2 is linked to neoplasm.